Nivolumab, Contact Immunotx Treats In-Transit Melanoma

This article originally appeared here.
Share this content:
Nivolumab, Contact Immunotx Treats In-Transit Melanoma
Nivolumab, Contact Immunotx Treats In-Transit Melanoma

TUESDAY, Jan. 12, 2016 (HealthDay News) -- Nivolumab in combination with contact immunotherapy can successfully treat in-transit melanoma, according to two case reports published online Dec. 12 in the Journal of Dermatology.

Taku Fujimura, M.D., Ph.D., from the Tohoku University Graduate School of Medicine in Sendai, Japan, and colleagues describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy.

Firstly, the authors describe the case of a 68-year-old man with multiple nodules and prominent lymph edema on his left foot. He was diagnosed with in-transit melanoma. The patient was administered squaric acid dibutylester every two weeks. Three months after administration, focal vitiligo developed around the in-transit metastases, and nivolumab was administered. Almost all the in-transit metastasis was diminished with prominent vitiligo at six months after nivolumab administration. The second patient was an 83-year-old woman with multiple nodules and edema on her left lower extremities. She was also diagnosed with in-transit melanoma, and was topically administered diphencyprone every two weeks. Two months later, extensive vitiligo developed in the lower left extremities and nivolumab was administered. Almost all in-transit metastasis had diminished with prominent vitiligo at six months after nivolumab administration.

"Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »